公司全年实现营业收入7.68亿元，同比增长3.26%；归母净利润0.79亿元，同比下降23.55%。收入仍在增 长，但利润却出现明显下滑——当营收与利润开始"反向走"，问题往往不在市场，而在成本结构。 整体来看，公司处于 "收入稳、利润降"的典型阶段 ，增长质量短期受到影响。 利润下滑核心：研发投入与折旧摊销提升 利润承压的核心原因主要来自成本端和费用端的上升。 2026年2月27日， 翔宇医疗（688626） 发布2025年业绩快报： 一方面，公司持续加大研发投入，引进高端康复技术人才，研发人员薪酬及相关费用增加，带动整体费用 上行。 另一方面，随着前期建设项目陆续投入使用，折旧与摊销费用明显增加，对利润形成持续压制。 在此背景下，公司虽然维持了收入增长，但利润端被"费用扩张"显著侵蚀，尤其扣非净利润降幅达到 34.48%，反映主营盈利能力的实际压力更为明显。 | | | 81 | | --- | --- | --- | | V | 12 | | | . 1.0 | | | | | | . | | IL | | | | 1 1 | | 1 | | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | ...

经济观察网翔宇医疗(688626)2026年有多项已公告或计划中的事件值得关注。 产品研发进展 公司计划在2026年推出数十款脑机接口等新产品，进一步丰富康复医疗设备矩阵，并将脑机接口技术升 级至多模态、多范式体系。 公司业绩目标 脑机接口相关产品预计在2026年对业绩提升起到较大促进作用，目前已在150余家大型医院进行临床使 用与课题合作。 公司项目推进 高管变动 公司控股股东一致行动人安阳启旭贸易咨询服务中心(有限合伙)计划于2026年2月4日至5月3日期间减持 不超过公司总股本3%的股份。 公司目标在2026年将产品覆盖扩展至超1000家三甲医院，目前产品已进入500多家三甲医院。 业务进展情况 公司正积极推进投资并购事宜，以整合行业资源，投融资工作有序进行中。此外，公司牵头申报的河南 省脑机接口康复设备技术创新中心已于2026年1月获批成为省级平台，可能持续推动技术研发。 以上内容基于公开资料整理，不构成投资建议。 ...

Group 1 - The brain-computer interface (BCI) industry has introduced a new standard titled "Technical Requirements and Testing Methods for EEG-based Fatigue State Monitoring Systems," which aims to fill the existing gap in industry standards [1] - The standard was developed by the China Academy of Information and Communications Technology in collaboration with over 30 institutions, including Capital Medical University Xuanwu Hospital, Zhejiang University, and Tsinghua University, to clarify the working principles, structure, technical requirements, and testing methods of relevant systems [1] - Henan Xiangyu Medical Equipment Co., Ltd. played a significant role in drafting the standard, leveraging its expertise in rehabilitation and BCI technology integration [1] Group 2 - The BCI industry is currently experiencing a critical period of technological iteration and expansion of application scenarios, with both invasive and non-invasive technology paths developing concurrently [1] - Invasive technology requires surgical implantation of electrodes for high-precision brain signal acquisition, which limits its scalability due to high risks and costs, while non-invasive technology, such as EEG caps, is safer and more convenient for health monitoring and rehabilitation [2] - The rehabilitation equipment industrial park in Anyang City has attracted 62 upstream and downstream enterprises, including Xiangyu Medical, creating a complete industrial chain that integrates research, manufacturing, and services [2]

Industry Overview - The rehabilitation medical industry is becoming one of the most promising sectors in the health care field, driven by an aging population, upgraded health consumption, and increased policy support [1][4] - The recent "Belt and Road" Central Rehabilitation Medicine Forum and Rehabilitation Equipment Expo attracted nearly 3,000 experts, scholars, and representatives from enterprises and investment institutions, indicating strong interest and investment potential in the sector [1] Strategic Collaborations - A strategic cooperation framework agreement was signed among seven cities in three provinces, focusing on resource sharing, technology collaboration, industrial linkage, and talent exchange to enhance the regional smart health industry [1] Technological Advancements - The establishment of the "Brain-Computer Interface Rehabilitation Technology Innovation Alliance" marks a shift from technology research to collaborative application in the brain-computer interface rehabilitation field [2] - The signing of key projects in five areas, including smart rehabilitation aids and brain-computer interface technology, aims to integrate resources along the industrial chain and promote the development of the smart rehabilitation equipment industry in Anyang [2] Market Trends - The exhibition showcased a wide range of cutting-edge rehabilitation products and technologies, highlighting the industry's evolution towards intelligent and integrated rehabilitation solutions [3] - The demand for rehabilitation devices is increasing, reflecting a trend towards specialization and segmentation in the rehabilitation market, with a focus on various fields such as neurological, traditional Chinese medicine, and pediatric rehabilitation [3][4] Company Insights - Xiangyu Medical, a leading company in rehabilitation medical devices, is at the forefront of innovation, having launched 14 new brain-computer interface products that cover multiple rehabilitation scenarios [3] - The company is expected to benefit from the implementation of the "Healthy China 2030" plan, as the demand for rehabilitation equipment and services continues to grow [3][4]

Economic Overview - As of October 31, all 31 provinces in China have released their Q3 reports for 2025, revealing significant changes in the economic landscape as the year-end approaches [1] - Guangdong, Jiangsu, and Shandong remain the top three provinces by GDP, with Guangdong leading at 105,176.98 billion yuan, followed by Jiangsu at 102,811 billion yuan, and Shandong at 77,115 billion yuan [1][5] Economic Growth - Central and western provinces, such as Hubei and Tibet, have shown impressive GDP growth rates, with Hubei achieving 6.0% and Tibet 7.1%, the highest in the country [1][8] - Hubei's GDP growth is supported by strong performance in consumption, investment, and exports, with a notable 30.8% increase in export value [9][10] Industrial Development - The industrial sector, particularly high-tech manufacturing, has been a key driver of GDP growth across multiple provinces [11] - Guangdong's industrial output increased by 3.5%, with advanced manufacturing and high-tech manufacturing growing by 5.4% and 6.4%, respectively [5][6] - Jiangsu's high-tech industry also performed well, with a 11.7% increase in output, contributing significantly to overall industrial growth [6] Policy Initiatives - Guangdong has introduced measures to boost industrial investment, focusing on sectors like solid-state batteries and electric vertical takeoff and landing vehicles [2][14] - Sichuan has announced policies to incentivize industrial project completion, offering up to 1.5 million yuan in rewards for successful projects [2][15] Export Performance - High-tech products have driven export growth, with Hubei's exports of electromechanical products reaching 2,191.7 billion yuan, a 19.8% increase [10] - In Henan, exports of new energy vehicles and lithium batteries surged, with electric vehicle exports alone growing by 262.1% [12] Market Trends - The demand for high-tech products, such as the "new three samples," is increasing both domestically and internationally, prompting industrial expansion [13] - Companies are adapting to market demands by increasing production capacity and investing in technology [13]

Core Insights - The company is focusing on the development of precise neuro-regulation technologies, particularly in the fields of transcranial magnetic stimulation for targeted treatments of mental health disorders such as depression and anxiety [1] - The management expressed confidence in the future potential of the rehabilitation industry, highlighting the diversification of rehabilitation service models extending from hospitals to communities and homes [1][2] Group 1: Research and Development Focus - In the magnetic stimulation field, the company aims to deepen research on targeted treatment solutions for mental health disorders and accelerate international registration of its products [1] - The electrical stimulation sector will see the development of an intelligent electrical stimulation system that supports multi-module combinations, integrating biofeedback technology for comprehensive product certification and market launch [1] - The company is advancing the application of intelligent rehabilitation robots and transcranial magnetic solutions in the rehabilitation market [1] Group 2: Market Strategy and Industry Positioning - The company plans to increase marketing and product promotion resources in the rehabilitation industry to seize growth opportunities and expand its business scale [2] - The integration of the rehabilitation industry and the rise of leading enterprises will be a gradual process, potentially taking 3-5 years, influenced by innovation speed, policy strength, and evolving demand [2] - The company aims to maintain a competitive edge by leveraging its technological advantages, brand influence, and resource integration capabilities [2] Group 3: AI Technology Integration - The company is actively incorporating AI technology into its product design to enhance automation and intelligence levels, such as in the MagNeuro ONE series for precise treatment targeting [2][3] - AI-driven technologies are being utilized to optimize laser energy management and improve operational automation in treatment processes [3] - The company is exploring AI applications in various fields, including biofeedback, brain function, and rehabilitation robotics, to facilitate the transition to intelligent rehabilitation [3] Group 4: Brain-Computer Interface Development - The company possesses a rich portfolio of products and technologies in the non-invasive brain-computer interface sector, including various biofeedback systems [3][4] - It has secured numerous patents related to brain signal acquisition and processing, enhancing its capabilities in the brain-computer interface domain [4] - The company's technology layout in neurological rehabilitation has evolved to provide comprehensive solutions across the diagnostic, treatment, and rehabilitation spectrum [4] Group 5: Personalized Rehabilitation Solutions - For stroke patients, the company utilizes EEG caps to capture movement imagination signals, triggering rehabilitation robots for training while enhancing neural plasticity through transcranial magnetic stimulation [5] - For spinal cord injury patients, the company employs surface electromyography systems to assess residual nerve function, creating personalized rehabilitation plans [5]

Group 1: Xiangyu Medical - The brain-computer interface (BCI) shows clear prospects in rehabilitation, potentially shifting patients from "passive rehabilitation" to "active rehabilitation," reducing labor costs and improving outcomes [1] - The company has an integrated advantage with "BCI technology + proprietary rehabilitation equipment," having obtained registration for two EEG collection devices, with over 20 devices expected to be certified by year-end and nearly 100 by the end of next year [1] - More than 50 large hospitals are currently using the company's equipment, which is expected to contribute to performance in 2025 and significantly enhance performance in 2026 [1] - R&D investment has increased by 38.80% year-on-year, with 117 new patents added, totaling 1,933 patents, including several related to BCI technology [1] - The sales model starts with partnerships with top-tier hospitals to create benchmarks, gradually extending to grassroots levels and eventually entering the home market [1] Group 2: Fenghua Gaoke - In the first half of 2025, the company aims to achieve record highs in product sales and revenue through cost reduction, efficient innovation, and new market development [2] - Automotive electronics sales increased by 39% year-on-year, communications by 22%, industrial control by 21%, and sales to the top ten customers grew by 27% [2] - Supercapacitor sales surged by 138%, with breakthroughs in emerging markets such as computing power, energy storage, intelligent robotics, and low-altitude economy [2] - The company has launched new products including medium and high-voltage MLCCs, MI series alloy resistors, and S series automotive-grade thick film precision resistors, emphasizing high reliability, miniaturization, and high precision [2] - A pricing strategy based on market supply and demand has been implemented to optimize product structure and improve gross margins [2] - The company has initiated a successor plan for talent management and is attracting core technical teams [2] - A "1+2+4+4+N" strategy has been established to promote high-quality development through seven strategic initiatives and various special projects [2]

Group 1 - Chengyitong Control Technology Group Co., Ltd. was established in 2003 and successfully listed on the Shenzhen Stock Exchange in 2015, specializing in intelligent manufacturing system solutions for the biopharmaceutical industry and rehabilitation medical equipment manufacturing [1] - The company has experienced a decline in stock price, with a cumulative drop of -7.15% over four consecutive trading days as of August 21 [1] - In the second quarter of this year, GF Fund's GF Jufeng Mixed A Fund increased its holdings in Chengyitong, achieving a year-to-date return of 22.52%, ranking 1819 out of 4492 in its category [1] Group 2 - The manager of GF Jufeng Mixed A Fund is Su Wenjie, who has a background in industry research and has been with GF Fund since 2015 [3][4] - Su Wenjie has managed various funds, including GF Resource Selection Stock Fund and GF Carbon Neutral Theme Mixed Fund, and has been appointed to manage multiple funds in the coming years [4] - GF Fund Management Co., Ltd. was established in August 2003, with major shareholders including GF Securities Co., Ltd. holding 54.53% [4]

Core Viewpoint - Chengyitong's stock price increased by 7.83% to 24.65 yuan, indicating strong market interest and positive investor sentiment towards the company's strategic initiatives in brain-computer interface technology [1]. Group 1: Company Performance - As of August 13, 2025, Chengyitong's stock closed at 24.65 yuan, up by 1.79 yuan from the previous trading day, with a trading volume of 542,300 shares and a total transaction value of 1.291 billion yuan [1]. - The stock opened at 22.69 yuan, reached a high of 24.87 yuan, and a low of 22.50 yuan during the trading session [1]. Group 2: Business Strategy - Chengyitong operates in the general equipment sector, focusing on smart manufacturing and rehabilitation medical devices [1]. - The company has established a dual-track strategy for brain-computer interface technology, encompassing both invasive and non-invasive approaches [1]. - In the non-invasive sector, Chengyitong is integrating existing rehabilitation devices with brain-computer interface technology to enhance product functionality and promote commercialization [1]. - The company has launched a brain-computer interface biofeedback system aimed at attention detection and training in the education sector [1]. - In the invasive sector, Chengyitong is developing a research verification center and an animal testing center for brain-computer interface technology to strengthen its R&D capabilities [1]. Group 3: Financial Flow - On August 13, 2025, the net inflow of main funds into Chengyitong was 41.04 million yuan, with a cumulative net inflow of 28.52 million yuan over the past five days [2].

Core Viewpoint - Multiple listed companies' controlling shareholders have made commitments not to reduce their holdings, reflecting confidence in the companies' future development and contributing to market stability [1][3]. Group 1: Commitments from Controlling Shareholders - Companies such as Xiangyu Medical, Wanhua Chemical, Guo New Energy, and Jinjiang Hotels have announced commitments from their controlling shareholders to refrain from selling shares for a period of 12 months [1][2]. - Xiangyu Medical's controlling shareholder, Henan Xiangyu Health Industry Management Co., Ltd., and its actual controllers have committed not to reduce their holdings from March 12, 2024, to March 11, 2025 [2]. - Wanhua Chemical's controlling shareholders have also expressed confidence in the company's future and committed to not reducing their holdings for the next 12 months [2]. Group 2: Market Stability and Confidence - The trend of controlling shareholders making long-term commitments not to sell shares is seen as a way to bolster market confidence and protect the interests of all shareholders [3][6]. - The recent increase in commitments from controlling shareholders comes amid a turbulent secondary market, with many companies taking measures to stabilize their stock prices [3][6]. Group 3: Positive Business Performance - Xiangyu Medical reported a significant increase in revenue and net profit for 2023, with total revenue reaching 745 million yuan, a year-on-year increase of 52.46%, and net profit of 230 million yuan, up 82.96% [4]. - Wanhua Chemical achieved total revenue of 175.36 billion yuan in 2023, a 5.92% increase from the previous year, with net profit of 16.81 billion yuan, reflecting a 3.57% growth [5].